- Home
- NAC vs TVTX Comparison
NAC vs TVTX Comparison
Compare NAC & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAC
- TVTX
- Stock Information
- Founded
- NAC 1998
- TVTX 2008
- Country
- NAC France
- TVTX United States
- Employees
- NAC N/A
- TVTX N/A
- Industry
- NAC Investment Managers
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- NAC Finance
- TVTX Health Care
- Exchange
- NAC Nasdaq
- TVTX Nasdaq
- Market Cap
- NAC 1.6B
- TVTX 1.4B
- IPO Year
- NAC N/A
- TVTX N/A
- Fundamental
- Price
- NAC $11.22
- TVTX $14.89
- Analyst Decision
- NAC
- TVTX Strong Buy
- Analyst Count
- NAC 0
- TVTX 16
- Target Price
- NAC N/A
- TVTX $33.33
- AVG Volume (30 Days)
- NAC 307.3K
- TVTX 1.5M
- Earning Date
- NAC 01-01-0001
- TVTX 07-31-2025
- Dividend Yield
- NAC 4.33%
- TVTX N/A
- EPS Growth
- NAC N/A
- TVTX N/A
- EPS
- NAC N/A
- TVTX N/A
- Revenue
- NAC N/A
- TVTX $273,533,000.00
- Revenue This Year
- NAC N/A
- TVTX $73.84
- Revenue Next Year
- NAC N/A
- TVTX $46.72
- P/E Ratio
- NAC N/A
- TVTX N/A
- Revenue Growth
- NAC N/A
- TVTX 75.65
- 52 Week Low
- NAC $9.32
- TVTX $7.72
- 52 Week High
- NAC $11.21
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- NAC 67.71
- TVTX 45.34
- Support Level
- NAC $10.98
- TVTX $14.36
- Resistance Level
- NAC $11.25
- TVTX $15.27
- Average True Range (ATR)
- NAC 0.07
- TVTX 0.61
- MACD
- NAC 0.02
- TVTX 0.15
- Stochastic Oscillator
- NAC 87.93
- TVTX 71.13
About NAC Nuveen California Quality Municipal Income Fund
Nuveen California Quality Municipal Income Fund is a diversified closed-end management investment company. Its objective is to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal and California state income taxes. It invests majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.